Compare NEULAND LABS with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NEULAND LABS vs PFIZER - Comparison Results

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NEULAND LABS PFIZER NEULAND LABS/
PFIZER
 
P/E (TTM) x 65.3 50.3 129.7% View Chart
P/BV x 4.9 8.4 59.1% View Chart
Dividend Yield % 0.1 0.4 17.9%  

Financials

 NEULAND LABS   PFIZER
EQUITY SHARE DATA
    NEULAND LABS
Mar-20
PFIZER
Mar-19
NEULAND LABS/
PFIZER
5-Yr Chart
Click to enlarge
High Rs7543,840 19.6%   
Low Rs2472,080 11.9%   
Sales per share (Unadj.) Rs594.5455.0 130.7%  
Earnings per share (Unadj.) Rs12.693.8 13.5%  
Cash flow per share (Unadj.) Rs37.0109.4 33.8%  
Dividends per share (Unadj.) Rs2.0022.50 8.9%  
Dividend yield (eoy) %0.40.8 52.6%  
Book value per share (Unadj.) Rs553.4658.2 84.1%  
Shares outstanding (eoy) m12.8345.75 28.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.86.5 12.9%   
Avg P/E ratio x39.631.6 125.5%  
P/CF ratio (eoy) x13.527.1 50.0%  
Price / Book Value ratio x0.94.5 20.1%  
Dividend payout %15.824.0 66.0%   
Avg Mkt Cap Rs m6,421135,420 4.7%   
No. of employees `0001.32.6 48.7%   
Total wages/salary Rs m1,2363,238 38.2%   
Avg. sales/employee Rs Th5,949.47,911.4 75.2%   
Avg. wages/employee Rs Th963.81,230.9 78.3%   
Avg. net profit/employee Rs Th126.41,630.7 7.8%   
INCOME DATA
Net Sales Rs m7,62720,815 36.6%  
Other income Rs m391,674 2.3%   
Total revenues Rs m7,66622,489 34.1%   
Gross profit Rs m1,0195,712 17.8%  
Depreciation Rs m313714 43.8%   
Interest Rs m21673 295.9%   
Profit before tax Rs m5296,599 8.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3672,309 15.9%   
Profit after tax Rs m1624,291 3.8%  
Gross profit margin %13.427.4 48.7%  
Effective tax rate %69.435.0 198.3%   
Net profit margin %2.120.6 10.3%  
BALANCE SHEET DATA
Current assets Rs m5,15227,167 19.0%   
Current liabilities Rs m3,5768,917 40.1%   
Net working cap to sales %20.787.7 23.6%  
Current ratio x1.43.0 47.3%  
Inventory Days Days10568 155.0%  
Debtors Days Days9130 301.9%  
Net fixed assets Rs m3,9698,862 44.8%   
Share capital Rs m129458 28.2%   
"Free" reserves Rs m6,97129,656 23.5%   
Net worth Rs m7,10030,113 23.6%   
Long term debt Rs m77425 3,094.8%   
Total assets Rs m12,31039,400 31.2%  
Interest coverage x3.591.5 3.8%   
Debt to equity ratio x0.10 13,126.8%  
Sales to assets ratio x0.60.5 117.3%   
Return on assets %3.111.1 27.7%  
Return on equity %2.314.2 16.0%  
Return on capital %9.522.1 42.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m5,187428 1,211.0%   
Fx outflow Rs m1,593786 202.5%   
Net fx Rs m3,594-358 -1,003.6%   
CASH FLOW
From Operations Rs m573978 58.6%  
From Investments Rs m-487351 -138.6%  
From Financial Activity Rs m-55-1,099 5.0%  
Net Cashflow Rs m33231 14.1%  

Share Holding

Indian Promoters % 36.3 0.0 -  
Foreign collaborators % 0.0 63.9 -  
Indian inst/Mut Fund % 63.7 7.5 849.7%  
FIIs % 0.0 4.9 -  
ADR/GDR % 0.0 0.0 -  
Free float % 63.7 23.7 268.9%  
Shareholders   12,705 85,207 14.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NEULAND LABS With:   SUN PHARMA  PROCTER & GAMBLE HEALTH  GSK PHARMA  FULFORD INDIA  ORCHID PHARMA  

Compare NEULAND LABS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 244 Points Lower, Nifty Ends Below 14,300; UltraTech Cement & HCL Tech Top Losers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended lower.

Related Views on News

PFIZER Announces Quarterly Results (3QFY21); Net Profit Up 1.6% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, PFIZER has posted a net profit of Rs 1 bn (up 1.6% YoY). Sales on the other hand came in at Rs 6 bn (up 10.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.

NEULAND LABS Announces Quarterly Results (3QFY21); Net Profit Up 141.5% (Quarterly Result Update)

Feb 3, 2021 | Updated on Feb 3, 2021

For the quarter ended December 2020, NEULAND LABS has posted a net profit of Rs 267 m (up 141.5% YoY). Sales on the other hand came in at Rs 2 bn (up 20.5% YoY). Read on for a complete analysis of NEULAND LABS's quarterly results.

PFIZER Announces Quarterly Results (2QFY21); Net Profit Down 14.8% (Quarterly Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

For the quarter ended September 2020, PFIZER has posted a net profit of Rs 1 bn (down 14.8% YoY). Sales on the other hand came in at Rs 6 bn (up 5.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

NEULAND LABS 2019-20 Annual Report Analysis (Annual Result Update)

Sep 2, 2020 | Updated on Sep 2, 2020

Here's an analysis of the annual report of NEULAND LABS for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of NEULAND LABS. Also includes updates on the valuation of NEULAND LABS.

PFIZER Announces Quarterly Results (1QFY21); Net Profit Up 10.3% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, PFIZER has posted a net profit of Rs 1 bn (up 10.3% YoY). Sales on the other hand came in at Rs 5 bn (down 5.4% YoY). Read on for a complete analysis of PFIZER's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

11x Bankruptcy to Bluechip Stock: A Rare India Revival Story(Profit Hunter)

Apr 16, 2021

There is no stopping this 11-bagger stock from significant upside.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

A Warning About Bubbles(Fast Profits Daily)

Apr 16, 2021

Those who don't learn from financial history are doomed to lose their money.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

NEULAND LABS SHARE PRICE


Apr 20, 2021 03:36 PM

TRACK NEULAND LABS

  • Track your investment in NEULAND LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NEULAND LABS - BIOCON COMPARISON

COMPARE NEULAND LABS WITH

MARKET STATS